Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 2Phase 3 2

Status

Unknown 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 1Breast 1

Conditions

Breast Neoplasms 1883Carcinoma, Non-Small-Cell Lung 1345Prostatic Neoplasms 980Colorectal Neoplasms 848Multiple Myeloma 740Leukemia, Myeloid, Acute 725Neoplasms 689Lung Neoplasms 678Neoplasm Metastasis 642Lymphoma 579Carcinoma, Hepatocellular 571Pancreatic Neoplasms 566Stomach Neoplasms 522Leukemia 511Recurrence 490Leukemia, Lymphocytic, Chronic, B-Cell 459Precursor Cell Lymphoblastic Leukemia-Lymphoma 452Melanoma 450Lymphoma, Non-Hodgkin 442Ovarian Neoplasms 426Lymphoma, Large B-Cell, Diffuse 422Myelodysplastic Syndromes 416Squamous Cell Carcinoma of Head and Neck 415Head and Neck Neoplasms 402Brain Neoplasms 402Rectal Neoplasms 395Glioblastoma 374Carcinoma, Renal Cell 349Hodgkin Disease 338Lymphoma, Follicular 336

Interventions

pamiparib 1enzalutamide 1apalutamide 1abiraterone 1Prednisone 1Prednisolone 1Poly(ADP-ribose) Polymerase Inhibitors 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × OTHER × Neoadjuvant Therapy × Clear all
NCT07054242 2025-10-01

A Prospective, Single-center, Phase II Study of Sacituzumab Tirumotecan in Combination With Pembrolizumab for Neoadjuvant Treatment of Triple-Negative Breast Cancer (TNBC)

Yantai Yuhuangding Hospital

Phase 2 Not yet recruiting
52 enrolled
Breast

Neoadjuvant Therapy

NCT05376722 2023-01-05

A Study of Pamiparib Combined With Abiraterone Acetate in Neoadjuvant Treatment of Prostate Cancer

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 2 Unknown
30 enrolled

Neoadjuvant Therapy

NCT05406999 2022-08-16

Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 2 Recruiting
900 enrolled
Genitourinary

Neoadjuvant Therapy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡